1. Home
  2. FOSL vs PLX Comparison

FOSL vs PLX Comparison

Compare FOSL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fossil Group Inc.

FOSL

Fossil Group Inc.

HOLD

Current Price

$3.61

Market Cap

209.2M

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.09

Market Cap

168.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOSL
PLX
Founded
1984
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.2M
168.1M
IPO Year
1993
1998

Fundamental Metrics

Financial Performance
Metric
FOSL
PLX
Price
$3.61
$2.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$12.00
AVG Volume (30 Days)
424.8K
777.6K
Earning Date
03-11-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
$1,066,179,000.00
$61,840,000.00
Revenue This Year
N/A
$14.29
Revenue Next Year
N/A
$16.65
P/E Ratio
N/A
$30.11
Revenue Growth
N/A
35.41
52 Week Low
$0.86
$1.32
52 Week High
$4.40
$3.10

Technical Indicators

Market Signals
Indicator
FOSL
PLX
Relative Strength Index (RSI) 47.15 63.87
Support Level $3.66 $1.97
Resistance Level $4.01 $2.11
Average True Range (ATR) 0.24 0.10
MACD -0.05 0.02
Stochastic Oscillator 10.17 89.16

Price Performance

Historical Comparison
FOSL
PLX

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: